Home Business Novartis says lung cancer drug canakinumab failed phase III trial

Novartis says lung cancer drug canakinumab failed phase III trial

34 second read
Comments Off on Novartis says lung cancer drug canakinumab failed phase III trial
0
39


Article content

ZURICH — Novartis said on Monday its canakinumab drug to help treat non-small cell lung cancer failed a phase III trial.

The drug, used as an adjuvant treatment, did not meet its primary endpoint of disease-free survival, the Swiss company said. (Reporting by John Revill; Editing by Christian Schmollinger)



Source link

Load More Related Articles
Load More By 
Load More In Business
Comments are closed.

Check Also

year JGB yield falls, longer-term notes keep rising

Article content TOKYO — The Japanese government bond market moved in mixed directions on W…